Inaktiver Wert

Andere Sprachen Matinas BioPharma Holdings Inc Other OTC

Aktien

US5768101058

Schlusskurs Other OTC Andere Börsenplätze
- ^USD	-

09.05.	Transcript : Matinas BioPharma Holdings, Inc., Q1 2024 Earnings Call, May 09, 2024
09.05.	Matinas BioPharma Holdings, Inc. meldet Ergebnis für das erste Quartal zum 31. März 2024	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

New In Vitro Data Showing Matinas BioPharma’s LNC Platform Delivering Small Oligonucleotides Presented at TIDES USA 2024	16.05.
New In Vitro Data Showing Matinas BioPharma’s LNC Platform Delivering Small Oligonucleotides Presented at TIDES USA 2024	16.05.
Matinas BioPharma Reports First Quarter 2024 Financial Results and Provides a Business Update	09.05.
Matinas BioPharma Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09.05.
Matinas BioPharma’s LNC Platform for the Delivery of Small Oligonucleotides Featured in Two Presentations at the ASGCT Annual Meeting	07.05.
Matinas BioPharma to Webcast Conference Call to Discuss First Quarter 2024 Financial Results and Provide a Business Update on May 9, 2024	02.05.
In Vivo Efficacy of Matinas BioPharma's Oral MAT2203 in Pulmonary Mucormycosis Published in Journal of Antimicrobial Agents and Chemotherapy	01.05.
In Vivo Efficacy of Matinas BioPharma’s Oral MAT2203 in Pulmonary Mucormycosis Published in Journal of Antimicrobial Agents and Chemotherapy	30.04.
In Vivo Efficacy of Matinas BioPharma?s Oral MAT2203 in Pulmonary Mucormycosis Published in Journal of Antimicrobial Agents and Chemotherapy	30.04.
Matinas BioPharma Prices $10 Million Registered Direct Offering	03.04.
Matinas BioPharma Prices $10 Million Registered Direct Offering	03.04.
Matinas BioPharma Reports 2023 Financial Results and Provides a Business Update	27.03.
Matinas BioPharma Reports 2023 Financial Results and Provides a Business Update	27.03.
Matinas BioPharma Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	27.03.
Three Patients with Invasive Fusarium Infection in Matinas BioPharma's Oral MAT2203 Compassionate, Expanded Use Access Program Achieve Complete Clinical Response	25.03.
Matinas BioPharma Regains Compliance with NYSE American Continued Listing Standards	25.03.
Matinas BioPharma Announces Positive in vivo Safety Data with its Oral LNC-Docetaxel Formulation	25.03.
Matinas BioPharma Announces Positive in vivo Safety Data with its Oral LNC-Docetaxel Formulation	25.03.
Matinas Biopharma Announces Positive in Vivo Safety Data with Its Oral Lnc-Docetaxel Formulation	25.03.
Three Patients with Invasive Fusarium Infection in Matinas BioPharma’s Oral MAT2203 Compassionate/Expanded Use Access Program Achieve Complete Clinical Response	22.03.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Matinas BioPharma Holdings Inc Other OTC

Aktien

US5768101058

Andere Sprachen

Filter